ClinicalTrials.gg
TerminatedNCT01592201Updated Jun 25, 2014

A Comparative Study of Patient Satisfaction Between Continued Administration of Previous Antipsychotics Versus Switched Administration to Paliperidone ER in Non-satisfied Patients With Previous Antipsychotic Drug

A Phase 4 interventional study of Paliperdidone ER and Aripiprazole, olanzapine and risperidone (Antipsychotics) in Schizophrenia, sponsored by Janssen Korea, Ltd., Korea. Terminated at 9 sites in Korea, Republic of. Open to participants aged 20 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-06-25.

Sponsored by Janssen Korea, Ltd., Korea (part of Johnson & Johnson) · Phase 4, Interventional, and Treatment

Why this study was terminated
This study was early terminated due to insufficient enrollment required for hypothesis testing.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
13
Allocation
Randomized
Ages
20 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 652 studies testing antipsychotics in Schizophrenia — 23 open to participants now, 24 under way, 6 of them phase 3. A drug class: Antipsychotics · Schizophrenia.

Enrollment
601st of 644
13 · median 111
Started
2012
with 31 others
Phase 4
247 of 652
12 open now
Registered
425th of 652
by date

Among the 652 studies testing antipsychotics in Schizophrenia, this one is the 601st largest by enrollment of the 644 interventional ones that give a count, is one of 32 that started in 2012, is one of 247 in phase 4, and was the 425th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

23 of the 652 studies testing antipsychotics in Schizophrenia are open now, in 12 countries. Recruiting first, the newest first:

18 more — sign in →

By country, each count listing its studies:

All 23 open studies →

About antipsychotics

A class of medicines: which ones, and the studies of each, are on its page →

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 20 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 652 studies testing antipsychotics in Schizophrenia, or all of them as a file.
02

Study summary

The purpose of this study is to compare the patient satisfaction between continued administration of previous antipsychotics versus switched administration to paliperidone ER in non-satisfied patients with previous (paliperidone)

Read the detailed description

This is a randomized (patients are assigned to intervention by chance), prospective, open-label (all people involved know the identity of the assigned drug), switch study designed to evaluate patient-assessed medication satisfaction after 12 weeks of treatment in patients with schizophrenia. The total duration of this study is 12 weeks. Outpatients who treated atypical antipsychotics and report dissatisfaction (Medication Satisfaction Questionnaire [MSQ] \<4) with their current treatment response are eligible to participate in the study. Patients will be randomized into two groups, 1) Patients randomized to an immediate initiation of paliperidone ER for a total 12 weeks 2) Patients randomized to a delayed initiation will continue their previous atypical antipsychotics for 8 weeks and then be initiated on paliperidone ER at Day 56 for 4 weeks. During the study treatment optimization will be done by dose adjustment (dose increase or decrease) and by adding psychotropic agents except the antipsychotics.

03

Conditions studied

  • Schizophrenia

Keywords

  • Schizophrenia
  • Paliperidone ER
  • Antipsychotics
  • Mental disorder
  • Comparative study
04

Who can participate

Ages eligible
20 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must be diagnosed with schizophrenia according to the (DSM-IV) criteria
  • Have taken atypical antipsychotics (aripiprazole, olanzapine, risperidone) at least 6 weeks prior to start of study.
  • Have Medication Satisfaction Questionnaire (MSQ) score of ≤3
  • Competent patients who manage to answer the questionnaires

Exclusion criteria

Exclusion Criteria:

  • Have had a history or current symptoms of tardive dyskinesia or neuroleptic malignant syndrome
  • Have had relevant history of or current presence of any significant or unstable cardiovascular, respiratory, neurological (including seizures or significant cerebrovascular), renal, hepatic, hematologic, endocrine, immunologic, morbid obesity (≥40), or other systemic disease
  • Had received two or more different kind of antipsychotics.
  • Had a history of taking paliperidone extended release (ER).
  • Allergy or to risperidone or paliperidone ER.
  • Have been on clozapine or long-acting injectable antipsychotic medication during the last 3 months.
  • Have had Medication Satisfaction Questionnaire (MSQ) score>3
  • Have been hospitalized for longer than 8 continuous weeks during the past 6 months
  • Had history of any severe preexisting gastrointestinal narrowing (pathologic or iatrogenic) or inability to swallow the oral tolerability medication whole with the aid of water for patients requiring oral tolerability testing
  • Current substance dependence () or past history of dependence (more than 6 months)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    Paliperidone ER

    Immediate initiation of Paliperidone ER for a total of 12 weeks

    Drug: Paliperdidone ER

  • Experimental
    Antipsychotics and paliperidone ER

    Delayed initiation included previous atypical antipsychotics for 8 weeks and then be initiated on paliperidone ER at Day 56 for 4 weeks. The atypical antipsychotics includes aripiprazole, olanzapine and risperidone. These antipsychotics belongs to the class of second generation bipolar atypical antipsychotics.

    Drug: Paliperdidone ER · Drug: Aripiprazole, olanzapine and risperidone (Antipsychotics)

Interventions

  • DrugPaliperdidone ER

    Form = osmotic release oral system, route = oral

  • DrugAripiprazole, olanzapine and risperidone (Antipsychotics)

    Drug page: Antipsychotics

    Form = tablet, route = oral

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the medication satisfaction questionnaire (MSQ) score at Week 8

    A single-item, global, patient-completed instrument that is read aloud to patients by clinicians designed to assess treatment satisfaction among patients with schizophrenia. It consists of one question: "Overall, how satisfied are you with your current antipsychotic medication(s)?" with responses assessed on a 7-point scale rated as follows: 1 = extremely dissatisfied, 2=very dissatisfied, 3=somewhat dissatisfied, 4=neither satisfied nor dissatisfied, 5=somewhat satisfied, 6 = very satisfied, 7 = extremely satisfied

    Time frame: Baseline and Week 8

Secondary outcomes

  1. Positive and negative symptoms scale (PANSS) score

    The PANSS provides a total score (sum of the scores of all 30 items) and scores for 3 subscales, the positive subscale (7 items), the negative subscale (7 items), and the general psychopathology subscale (16 items), each rated on a scale of 1 (absent) to 7 (extreme). It's designed to capture symptoms of schizophrenia. (Gold standard)

    Time frame: Baseline to Week 12

  2. Drug Attitude Inventory (DAI)-10 Score

    DAI-10 is a 10-item scale developed to assess how the attitude of schizophrenia patients toward their medications may affect compliance (-10\~+10)

    Time frame: Baseline to Week 12

  3. Clinical Global Impression-Severity (CGI-S) Score

    The CGI-S rating scale is used to rate the severity of a patient's psychotic condition on a 7-point scale ranging from 1 (not ill) to 7 (extremely severe)

    Time frame: Baseline to Week 12

  4. Personal and Social Performance Scale (PSP)

    This scale assesses the degree of dysfunction a patient exhibits within 4 domains of behavior: socially useful activities, personal and social relationships, self-care, and disturbing and aggressive behavior. The score ranges from 1 to 100, divided into 10 equal intervals to rate the degree of difficulty (i, absent to vi, very severe) in each of the 4 domains. Based on the four domains there will be one total score. Patient's with a score of 71 to 100 have a mild degree of difficulty; from 31 to 70, varying degrees of disability; ≤ 30, functioning so poorly as to require intensive supervision

    Time frame: Baseline to Week 12

  5. Sleep Visual Analog Scale (Sleep VAS)

    This self-administered scale rates quality of sleep and daytime drowsiness. Patient's will indicate on an 11- point scale (from 0 to 10) how well they have slept in the previous 7 days ("very badly" to "very well") and how often they have felt drowsy within the previous 7 days ("not at all" to "all the time"). On the sleep evaluation scale, score '0' corresponds to 'very badly' and score '10' to 'very well'. On the daytime drowsiness scale, score '0' corresponds to 'not at all' and score '10' to 'all the time

    Time frame: Baseline to Week 12

  6. Number of patients with adverse events

    Time frame: Baseline to Week 12

  7. Number of patients with vital signs and physical examination

    Time frame: Baseline to Week 12

  8. Number of patients with laboratory test (prolactin, blood glucose, glycosylated hemoglobin, cholesterol, triglyceride)

    Time frame: Baseline to Week 12

07

Study locations

9 sites
  • Busan, Korea, Republic of
  • Cheonan City, Korea, Republic of
  • Chuncheon-Si, Korea, Republic of
  • Chungju-Si, Korea, Republic of
  • Dae-Gu, Korea, Republic of
  • Daejeon, Korea, Republic of
  • Goyang-Si, Korea, Republic of
  • Gyeonggi-Do, Korea, Republic of
  • Seoul, Korea, Republic of
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2012, a primary completion of Jun 2013 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2012
First posted
May 7, 2012
Start
Jul 2012
Primary completionActual
Jun 2013
CompletionActual
Jun 2013
Last update
Jun 25, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01592201
Responsible party
Sponsor
First posted
May 7, 2012
Start date
Jul 2012
Primary completion
Jun 2013
Completion
Jun 2013
Last update
Jun 25, 2014

Study contacts

Janssen Korea, Ltd., Korea Clinical Trial
study director · Janssen Korea, Ltd., Korea

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Antipsychotics

Start the discussion